<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993288</url>
  </required_header>
  <id_info>
    <org_study_id>TE_005_FER_CHT</org_study_id>
    <nct_id>NCT03993288</nct_id>
  </id_info>
  <brief_title>Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFER® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.</brief_title>
  <official_title>Multicenter, Open-label Active-controlled Randomized Study of Efficacy and Safety of Ferrum Lek® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia) Compared With Maltofer® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Vifor S.A., Switzerland), in Treatment of Patients With Mild and Moderate Iron-deficiency Anaemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate non-inferiority for efficacy and safety of Ferrum&#xD;
      Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia),&#xD;
      compared to MALTOFER® (Vifor S.A., Switzerland), in the treatment of patients with mild and&#xD;
      moderate iron-deficiency anaemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a multi-centric, open-label, randomized, prospective, comparative, parallel-group,&#xD;
      active-controlled, phase III clinical trial (in the Russian Federation).&#xD;
&#xD;
      The purpose of this study was to evaluate non-inferiority for efficacy and safety of Ferrum&#xD;
      Lek® (iron (III) hydroxide polymaltosate), compared to MALTOFER®, in the treatment of&#xD;
      patients with mild and moderate iron-deficiency anaemia.&#xD;
&#xD;
      Participants underwent screening for up to 7 days. Eligible participants were randomized in&#xD;
      1:1 ratio to two treatment arms.&#xD;
&#xD;
      Subjects in Group 1 received 2 tablets per day (200 mg) of chewable tablets Ferrum Lek®&#xD;
      during or immediately after meals; once daily.&#xD;
&#xD;
      Subjects in Group 2 (reference product) received 2 tablets per day (200 mg) of chewable&#xD;
      tablets Maltofer® during or immediately after meals; once daily.&#xD;
&#xD;
      The subjects received the medicinal products daily for 12 weeks. After the last scheduled&#xD;
      study site visit, a follow-up visit (by phone) was scheduled 14 days after the completion of&#xD;
      the active treatment period (day 98±2) to record any delayed adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Actual">June 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 18, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Blood Hemoglobin Level (g/L)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Changes in blood hemoglobin level (g/L) after 12-weeks of iron-deficiency anaemia treatment, a non-inferiority comparison, as compared with the baseline value (screening visit) between Ferrum Lek® and MALTOFER® groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Iron</measure>
    <time_frame>Baseline, Week 4, 8 and 12</time_frame>
    <description>Change in average values of iron metabolism parameter serum iron during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Transferrin</measure>
    <time_frame>Baseline, Week 4, 8 and 12</time_frame>
    <description>Change in average values of iron metabolism parameter transferrin during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Transferrin Saturation</measure>
    <time_frame>Baseline, Week 4, 8 and 12</time_frame>
    <description>Change in average values of iron metabolism parameter percent transferrin saturation during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ferritin</measure>
    <time_frame>Baseline, Week 4, 8 and 12</time_frame>
    <description>Change in average values of iron metabolism parameter ferritin during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Response to the Therapy</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Response to the therapy is determined as an increase in hemoglobin level by 20 g/L and more after 12-weeks of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">267</enrollment>
  <condition>Mild and Moderate Iron-deficiency Anaemia</condition>
  <arm_group>
    <arm_group_label>Ferrum Lek</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MALTOFER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)</intervention_name>
    <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
    <arm_group_label>Ferrum Lek</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)</intervention_name>
    <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
    <arm_group_label>MALTOFER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The signed and dated written informed consent prior to participation in the study.&#xD;
&#xD;
          2. Men and women aged 18 and older (by the time of screening).&#xD;
&#xD;
          3. Outpatients.&#xD;
&#xD;
          4. Diagnosed iron-deficiency anemia, based on two criteria:&#xD;
&#xD;
               1. hemoglobin level below 110 g/L (in men and women), but above 80 g/L,&#xD;
&#xD;
               2. serum ferritin levels below 30 µg/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Administration of any iron-containing drugs during the last 3 months.&#xD;
&#xD;
          2. History of erythropoietin drugs administration.&#xD;
&#xD;
          3. Hypersensitivity to iron therapy (both Oral and/or IV administration) and other&#xD;
             components of the study drugs.&#xD;
&#xD;
          4. Hormone therapy (including the use of androgens/anabolic steroids) or administration&#xD;
             of drugs that inhibit blood formation, less than 3 months before the start of the&#xD;
             study.&#xD;
&#xD;
          5. History of severe allergic reactions or drug intolerance.&#xD;
&#xD;
          6. Fructose intolerance, glucose-galactose malabsorption syndrome, and sucrase-isomaltase&#xD;
             deficiency.&#xD;
&#xD;
          7. Pregnant or lactating women, or women intending to become pregnant during the study.&#xD;
&#xD;
          8. Failure of iron therapy for iron-deficiency anaemia in a subject's past medical&#xD;
             history.&#xD;
&#xD;
          9. Heme metabolism disorders (e.g., sideroachrestic anaemia, lead anaemia, thalassaemia).&#xD;
&#xD;
         10. Iron overload including haemochromatosis and hemosiderosis&#xD;
&#xD;
         11. Other causes of anemia, apart from iron deficiency, including:&#xD;
&#xD;
               1. Haemolysis (determined as per analyses results at screening, or as per anamnestic&#xD;
                  data),&#xD;
&#xD;
               2. Vitamin B12 and folic acid deficiency (as per the screening data),&#xD;
&#xD;
               3. Chronic kidney disease (creatinine clearance at screening is below 90 ml/min&#xD;
                  (based on Cockcroft-Gault Formula)),&#xD;
&#xD;
               4. Systemic connective tissue diseases, chronic infectious diseases requiring&#xD;
                  regular therapy (as per the past medical history), and other conditions which&#xD;
                  may, in the investigator's opinion, be accompanied by anaemia of chronic&#xD;
                  diseases.&#xD;
&#xD;
         12. Dysfunction of the thyroid gland (based on the data obtained at screening).&#xD;
&#xD;
         13. Laboratory and clinical signs of an active inflammatory process for 10 days before&#xD;
             screening.&#xD;
&#xD;
         14. AST, ALT, and total bilirubin levels exceeding the upper limit of normal 1.5 times and&#xD;
             more.&#xD;
&#xD;
         15. Clinically apparent hypothyroidism, in the investigator's opinion.&#xD;
&#xD;
         16. Malignant diseases, including blood and lymphoid tissue disorders (leukemia, Hodgkin&#xD;
             disease, myelodysplastic syndrome, myeloma, etc.) at screening or in the past medical&#xD;
             history, provided that the remission was less than 5 years before screening.&#xD;
&#xD;
         17. Signs of bone marrow aplasia at screening or history of bone marrow aplasia.&#xD;
&#xD;
         18. The necessity of parenteral iron therapy, i.e. the following cases:&#xD;
&#xD;
               1. impaired absorption in case of an intestinal pathology (enteritis, coeliac&#xD;
                  disease, malabsorption, small intestinal resection, stomach resection, including&#xD;
                  the duodenum);&#xD;
&#xD;
               2. exacerbation of gastric or duodenal ulcer;&#xD;
&#xD;
               3. the necessity of quick iron saturation, e.g. in patients with iron-deficiency&#xD;
                  anaemia with upcoming surgery;&#xD;
&#xD;
               4. continuous vast blood loss and other causes, at the discretion of the&#xD;
                  investigator.&#xD;
&#xD;
         19. Known presence of an active infection caused by Helicobacter pylori. In case of&#xD;
             presence of Helicobacter pylori, a subject may be enrolled after eradicative therapy.&#xD;
&#xD;
         20. Concomitant diseases and conditions, which, in the investigator's opinion, pose risk&#xD;
             to a subject's safety in case of his/her participation in the study, or able to affect&#xD;
             the safety data analysis in case of exacerbation of this disease/condition during the&#xD;
             study, including:&#xD;
&#xD;
               1. Myocardial infarction or stroke within 6 months before screening.&#xD;
&#xD;
               2. Unstable angina;&#xD;
&#xD;
               3. Severe arrhythmia, not controlled by drug therapy;&#xD;
&#xD;
               4. Decompensated diabetes mellitus;&#xD;
&#xD;
               5. Nephrological disorders;&#xD;
&#xD;
               6. Other significant diseases, at the discretion of the investigator.&#xD;
&#xD;
         21. HIV infection (as per the screening data or the results of analysis performed within 6&#xD;
             months before screening).&#xD;
&#xD;
         22. Known or suspected drug or alcohol abuse for the last 2 years.&#xD;
&#xD;
         23. Suspected poor adherence of a subject (e.g., due to mental disorders).&#xD;
&#xD;
         24. Participation in any clinical drug studies less than 3 months before the study.&#xD;
&#xD;
         25. Blood donation / blood transfusion within 30 days prior to screening or planned blood&#xD;
             transfusion at time of screening.&#xD;
&#xD;
         26. History of smoking, unless leave off smoking &gt; 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz</last_name>
    <role>Study Director</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Krasnogorsk</city>
        <zip>143408</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>188643</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191186</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>192177</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>193232</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195197</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198207</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198328</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199226</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199406</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <results_first_submitted>June 18, 2021</results_first_submitted>
  <results_first_submitted_qc>June 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 12, 2021</results_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ferrum Lek® (iron (III) hydroxide polymaltosate)</keyword>
  <keyword>mild and moderate iron-deficiency anaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.</ipd_description>
    <ipd_access_criteria>This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03993288/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 6, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03993288/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 18 sites in the Russian Federation.</recruitment_details>
      <pre_assignment_details>Participants were randomized in 1:1 ratio to two treatment arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ferrum Lek</title>
          <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>MALTOFER</title>
          <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention-to-treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance to the inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>wrong randomization</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>improper enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>prescribed with prohibited concomitant therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>developed SAE</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>consent withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not follow the treatment schedule</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not follow the treatment regimen</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ferrum Lek</title>
          <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>MALTOFER</title>
          <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="267"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.68" lower_limit="18" upper_limit="71"/>
                    <measurement group_id="B2" value="38.16" lower_limit="18" upper_limit="73"/>
                    <measurement group_id="B3" value="38.92" lower_limit="18" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="249"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Blood Hemoglobin Level (g/L)</title>
        <description>Changes in blood hemoglobin level (g/L) after 12-weeks of iron-deficiency anaemia treatment, a non-inferiority comparison, as compared with the baseline value (screening visit) between Ferrum Lek® and MALTOFER® groups</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrum Lek</title>
            <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MALTOFER</title>
            <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Hemoglobin Level (g/L)</title>
          <description>Changes in blood hemoglobin level (g/L) after 12-weeks of iron-deficiency anaemia treatment, a non-inferiority comparison, as compared with the baseline value (screening visit) between Ferrum Lek® and MALTOFER® groups</description>
          <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.33" spread="15.05"/>
                    <measurement group_id="O2" value="18.52" spread="14.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was considered confirmed if the upper bound of the two-sided 95% confidence interval for the mean value calculated by the least squares method did not exceed the predetermined boundary of non-inferiority of 5 g/L</non_inferiority_desc>
            <p_value>0.0032</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.86</ci_lower_limit>
            <ci_upper_limit>4.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Iron</title>
        <description>Change in average values of iron metabolism parameter serum iron during the treatment period</description>
        <time_frame>Baseline, Week 4, 8 and 12</time_frame>
        <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrum Lek</title>
            <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MALTOFER</title>
            <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Iron</title>
          <description>Change in average values of iron metabolism parameter serum iron during the treatment period</description>
          <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
          <units>micromoles/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="7.35"/>
                    <measurement group_id="O2" value="3.42" spread="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="9.62"/>
                    <measurement group_id="O2" value="4.34" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.16" spread="9.56"/>
                    <measurement group_id="O2" value="6.12" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Transferrin</title>
        <description>Change in average values of iron metabolism parameter transferrin during the treatment period</description>
        <time_frame>Baseline, Week 4, 8 and 12</time_frame>
        <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrum Lek</title>
            <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MALTOFER</title>
            <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Transferrin</title>
          <description>Change in average values of iron metabolism parameter transferrin during the treatment period</description>
          <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.31"/>
                    <measurement group_id="O2" value="-0.14" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.41"/>
                    <measurement group_id="O2" value="-0.22" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.41"/>
                    <measurement group_id="O2" value="-0.25" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent Transferrin Saturation</title>
        <description>Change in average values of iron metabolism parameter percent transferrin saturation during the treatment period</description>
        <time_frame>Baseline, Week 4, 8 and 12</time_frame>
        <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrum Lek</title>
            <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MALTOFER</title>
            <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent Transferrin Saturation</title>
          <description>Change in average values of iron metabolism parameter percent transferrin saturation during the treatment period</description>
          <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
          <units>percent transferrin saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="5.82"/>
                    <measurement group_id="O2" value="4.44" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="12.54"/>
                    <measurement group_id="O2" value="5.47" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.27" spread="12.02"/>
                    <measurement group_id="O2" value="8.03" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ferritin</title>
        <description>Change in average values of iron metabolism parameter ferritin during the treatment period</description>
        <time_frame>Baseline, Week 4, 8 and 12</time_frame>
        <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrum Lek</title>
            <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MALTOFER</title>
            <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ferritin</title>
          <description>Change in average values of iron metabolism parameter ferritin during the treatment period</description>
          <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
          <units>microgram/liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="11.2"/>
                    <measurement group_id="O2" value="7.35" spread="33.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="14.72"/>
                    <measurement group_id="O2" value="4.49" spread="15.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="123"/>
                    <count group_id="O2" value="129"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.62" spread="20.24"/>
                    <measurement group_id="O2" value="6.55" spread="15.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Response to the Therapy</title>
        <description>Response to the therapy is determined as an increase in hemoglobin level by 20 g/L and more after 12-weeks of treatment</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferrum Lek</title>
            <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MALTOFER</title>
            <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response to the Therapy</title>
          <description>Response to the therapy is determined as an increase in hemoglobin level by 20 g/L and more after 12-weeks of treatment</description>
          <population>Intention-to-treat (ITT) population included all randomized participants who were administered at least one dose of the investigational product or comparator and who had hemoglobin level data both before and after treatment with the investigational product and the reference product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="129"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected for 14 weeks (12 weeks treatment period plus 2 weeks follow up).</time_frame>
      <desc>Any signs or symptoms that occurred for 14 weeks (12 weeks treatment period plus 2 weeks follow up).</desc>
      <group_list>
        <group group_id="E1">
          <title>Ferrum Lek</title>
          <description>Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>MALTOFER</title>
          <description>Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Stool discoloration</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

